On January 6, 2026, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced preliminary results for the company’s investigational treatments for obesity, ARO-INHBE and ARO-ALK7. The company also held ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of ...

Wave Life Sciences announced WVE-007, an siRNA treatment for obesity aimed at silencing INHBE to promote sustainable weight loss. Wave Life Sciences has announced the submission of a clinical trial ...

WVE-007 is a novel approach for treating obesity and is designed to silence INHBE to achieve healthy, sustainable weight loss through fat burning, muscle maintenance and the potential for once or ...

- Company hosting an obesity/metabolic R&D webinar today, August 14, 2024, at 2:00 pm ET as Part IV of the 2024 Summer Series of R&D Webinars PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead ...

Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable ...

- ARO-INHBE in combination with tirzepatide achieved -9.4% weight loss at week 16 in obese patients with type 2 diabetes mellitus, demonstrating an approximately two-fold improvement versus -4.8% on ...

Arrowhead Pharmaceuticals has reported early-phase data on a pair of gene silencing drug candidates in obesity, posting preliminary evidence that the molecules help people shed fat to send its stock ...